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2-Microglobulin is responsible for systemic amyloidosis
affecting patients undergoing long-term hemodialysis. Its
genetic variantD76Ncauses a very rare formof familial systemic
amyloidosis. These two types of amyloidoses differ significantly
in terms of the tissue localization of deposits and formajor path-
ological features. Considering how the amyloidogenesis of the
2-microglobulin mechanism has been scrutinized in depth for
the last three decades, the comparative analysis of molecular
and pathological properties of wild type 2-microglobulin and
of the D76N variant offers a unique opportunity to critically
reconsider the current understanding of the relation between
the protein’s structural properties and its pathologic behavior.
In 1984, George Glenner and Caine Wong (1) provided the
first chemical evidence that Alzheimer disease amyloid plaques
were constituted by -amyloid protein. The following year, the
Biochem. Biophys. Res. Commun. study by the Fumitake Gejyo
group (2) followed shortly after by the J. Clin. Invest. study by
the PeterGorevic andBlas Frangione team (3) both showed that
the constituent of amyloid deposits of patients treated with
chronic hemodialysis was the protein 2-microglobulin (2-
m).2 The further demonstration that the formation of amyloid
required a persistently high plasma concentration of 2-m (4)
was a clear proof that a critical concentration of a protein pre-
cursor is required for priming the formation of amyloid fibrils.
Hence, the early biochemical characterization clearly showed
that full-length non-mutated 2-m was abundantly present in
natural amyloid fibrils (5). Further biochemical studies were
carried out by Reynold Linke et al. (6) on different types of
tissues, which included specimens of the carpal tunnel, as well
as specimens derived from bone fractures caused by amyloid
deposits and even urinary stones. From these studies emerged
that in all natural amyloid deposits, the truncated species of
2-m lacking the six N-terminal residues was significantly rep-
resented (7). No other major post-translational modifications
are apparently present in natural fibrillar 2-m. In amyloid
deposits, the presence of the protein precursor’s fragments is
quite common.The truncation of extensive portions of the con-
stant region is common in amyloidogenic light chains. Natural
fibrils of apolipoprotein A-I mainly contain the N-terminal
polypeptide corresponding to the first 100 residues, and the
presence of transthyretin (TTR) fragments can be considered
almost a hallmark of the cardiac involvement in TTR amyloi-
dosis (8). The biochemical characterization of 2-m natural
amyloid fibrils highlighted the co-deposition of other macro-
molecules. Some of them, such as serum amyloid P component
(SAP) and glycosaminoglycans (GAGs), are generic co-constit-
uents of all types of systemic amyloidosis (9, 10), but a few are
apparently specifically associated with the 2-m-related form.
In an ante litteram proteomic study, Campistol et al. (11, 12)
showed that several anti-proteases are co-deposited in 2-m
natural fibrils and that the presence of 2-macroglobulin
(2-M) is particularly abundant. It is worth noting that a spe-
cific complex between 2-M and 2-m also circulates in the
plasma of hemodialysis patients (13). In 2012, the first natural
variant of 2-m was discovered in a French family where all the
heterozygous carriers of the mutation presented a multi-vis-
ceral amyloid deposit (14). Liver, kidney, and heart were all
involved, but unexpectedly, bones and ligaments were not
affected. This finding was quite surprising in terms of the
known tropism of theWT2-m for themuscle-skeletal system.
Another unexpected finding was the absence of WT 2-m in
the deposits, although its intrinsic amyloidogenic propensity is
well established. Equally surprising was the absence of N-ter-
minal truncated species, which are ubiquitous constituents of
2-m amyloid deposits in dialysis-related amyloidosis (DRA).
In the last two decades, the molecular characterization of
amyloid deposits caused byWT 2-m in patients under hemo-
dialysis, and more recently the molecular and pathological fea-
tures of the familial form of 2-m, have stimulated seminal
studies on the molecular basis of the amyloidogenesis of glob-
ular proteins in vivo, moving from totally artificial conditions to
more bio-compatible methods (Table 1). These studies have
provided new insights on the molecular basis of the intrinsic
predisposition to amyloid conversion and on the identification
of the physical-chemical conditions suitable in vivo to prime the
conformational transition, as well as some clues on the mecha-
nism responsible for the selective tissue targeting of amyloid
deposits in systemic amyloidosis.
2-m Fibrillogenesis in Vitro
The first successful attempt to obtain the fibrillar conversion
of native 2-mwas achieved by Connors et al. (15) immediately
after the identification of2-m as the causative protein of DRA.
This first method was based on the minimization of ion
strength and on the maximal increase of 2-m concentration.
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Although the yield was quite low, the study provided the first
demonstration that globular 2-m can be converted into fibrils
in vitro and that the concentration represents a crucial condi-
tion. Amore efficientmethod of2-m fibrillogenesis was intro-
duced in 1997 by Naiki et al. (16). In this case, the massive
conversion of 2-m into fibrils was primed by the presence of
seeds of natural fibrils and required a very low pH. Thismethod
highlighted how fibrillogenesis is accelerated by the presence of
fibrillar nuclei and in general how the amyloidogenesis requires
both a nucleation phase and an elongationphase.Moreover, the
low pH implied that the fibrillogenesis of the wild type required
the protein unfolding and was perfectly consistent with similar
evidences obtained in the same historical phase with other
globular amyloidogenic proteins, such as the lysozyme and
TTR variants (17, 18). Other ways to unfold the 2-m were
pursued by the Naiki group (19, 20) using SDS or trifluoroetha-
nol as mild protein denaturants. The possibility to transform
native 2-m into fibrils led to studies aiming to monitor major
conformational changes occurring during the transition and to
identify which part of the native molecule is substantially unal-
tered within the fibrils.
The work carried out by the Goto (21) and Radford (22)
teams revealed that low pH fibrillogenesis implies massive con-
formational changes of theN-terminal andC-terminal portions
of 2-m. However, the central core of the native protein con-
strained through its single disulfide bridge is apparently sub-
stantially conserved in the fibrils. These data were consistent
with the fact that the disulfide bridge bond (residues 25–80) is
necessary for the formation of fibrils in vitro and that when this
is reduced, the 2-m can only form amorphous aggregates (23).
Moreover, the disulfide bridge is present in natural amyloid
fibrils (24). The maintenance of the disulfide bond present in
the native protein precursors is common to other types of amy-
loidosis, and it is particularly meaningful for lysozyme fibrils,
where the four disulfide bonds of the native enzyme can be
found in the natural fibrils (17).
The structure of the natural fibrillar proteins is very inform-
ative and represents a profitable guide for designing proper
conditions of fibrillogenesis in vitro. This proposition was par-
ticularly true in relation to the evidence that truncated species
of 2-m were ubiquitously found in all the natural amyloid
deposits associated with DRA. The removal of six residues at
theN terminus of2-m (N62-m) has amassive impact on the
structure, on the stability, and on the fibrillogenic propensity of
2-m (25). N62-m rapidly forms fibrils in physiologic condi-
tions that are otherwise not permissive for full-length WT
2-m. Thismost likely plays a pivotal role in the pathogenesis of
the disease, and it can be considered a natural metastable con-
former suitable for the nucleation of 2-m fibrils. N62-m
rapidly forms oligomers in solution even at very low concentra-
tions, and it catalyzes the oligomerization of WT 2-m even in
a physiologic environment (26). The Radford group (27) has
extensively investigated the structural features of N62-m
and its capacity to recruit the WT into amyloid fibrils. The
NMR spectra revealed a remarkable overlapping of the struc-
ture of N62-m with the structure of the P32G variant that
was prepared to investigate the effect of the transition cis-trans
of Pro-32 on2-m fibrillogenesis.When Pro-32 is in cis confor-
mation, 2-m is protected from self-aggregation, whereas the
trans conformation makes the 2-m highly susceptible to a
rapid fibrillar conversion (28, 29).
The role of selective proteolytic cleavage in amyloidogenesis
has been extensively debated.However, there are still doubts on
the timeline of the proteolytic cleavage, notably if the event
precedes the fibrillar aggregation or if it simply represents a
process of trimming of the less protected portion of the poly-
peptide cemented in the amyloid fibrils. Unequivocal demon-
stration of a pre-fibrillogenic proteolytic event is still missing;
however, it is unquestionable that selective proteolytic cleavage
mimicking that occurring in vivo has a strong enhancing
effect on the kinetics of fibril formation of 2-m and other
proteins such as TTR (30). Despite the relevance of proteo-
lytic cleavage, some types of amyloid fibrils, such as those
formed in vivo by variants of lysozyme (17) and the natural
variant of 2-m D76N (14), only contain an intact and full-
length mature protein.
The discovery that in vitro truncated 2-m can form amyloid
fibrils, in a physiologic environment, hasmoved themethods of
in vitro fibrillogenesis towardmore bio-compatible conditions.
A successful example of a bridge between the known tropism of
2-m for themuscle skeletal system and an in vitromethod was
achieved by studying the effect of type I and type II collagen on
2-m amyloidogenesis (31). The effect of the interaction of
2-m with the collagen’s surface is remarkable, and Fig. 1 illus-
trates a representative image of the growth of amyloid fibrils
stemming from type I collagen fibers. The presence of 2-m
oligomers and GAGs was able to accelerate the process of the
TABLE 1
Summary of the different methods reported in literature to generate
2-m amyloid fibrils in vitro
Experimental conditions Reference
50 mM sodium citrate, pH 2.5–4, 37 °C 16
100 M 2-m in the presence of seeds
50 mM sodium citrate, 100 mM NaCl, pH 2.5, 37 °C 58
100 M 2-m
50 mM sodium citrate, pH 6.5, 37 °C 25
100 M N62-m in the presence of seeds
50 mM sodium citrate, pH 7.3, 37 °C 35
100 M refolding intermediate in the presence of seeds
50 mM sodium phosphate, 100 mM NaCl, pH 7.4, 0.5% SDS,
37 °C
19
25 M 2-m in the presence of seeds
50 mM sodium phosphate, 100 mM NaCl, pH 7.4, 20%
TFE,a 37 °C
20
100 M 2-m in the presence of heparin-stabilized seeds
25 mM sodium phosphate, pH7.0, 37 °C, stirring at 250 rpm 28
40 M 2-m in the presence of heparin, SAP,b
apolipoprotein E-stabilized seeds
50 mM ammonium acetate, pH 6.4, 20 M heparin, fibrillar
collagen type I, 37–40 °C
31, 32
40–50 M 2-m
1 M NaCl, pH 7.5, 37 °C, 24 h stirring, incubation without
agitation for 2545 days
59
30–60 M 2-m
1 M NaCl, pH 7.5, 60–70 °C, 24 h stirring 60
40–80 M 2-m
25 mM sodium phosphate, pH 7.4, 37 °C, stirring at 1500
rpm
40
40 M D76N 2-m
a TFE, trifluoroethanol.
b SAP, serum amyloid P component.
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amyloid grown on the collagen surface. This confirmed the
generic pro-amyloidogenic effect played by the aforementioned
components in fibrillogenesis (32). However, despite the
growth of fibrils on the collagen surface, in the absence of fluid
flow, the majority of the bulk of WT 2-m in solution was not
converted into fibrils on a time scale of several days.
2-m, similar to many other globular amyloidogenic pro-
teins, displays a strong propensity to spontaneously aggregate
into soluble oligomers; in particular, 2-m does so in the phys-
iologic buffer (26, 28, 33). It is likely that the oligomerization is
mainly primed by a small population of partially folded con-
formers in equilibriumwith the fully folded protein.NMR stud-
ies, molecular dynamic simulation, capillary electrophoresis,
and spectroscopic analysis highlighted the existence of a par-
tially folded intermediate, initially named I2 (34, 35), in which
specific regions of the molecule exhibit a very high flexibility and
rapid structural fluctuations (36). The fluctuation toward a par-
tially folded state is probably dictated by the peculiar dynamics of
the loop interconnecting the strands D and E. This loop is partic-
ularly unstable, most likely due to the presence of a tryptophan
(Trp-60) in the center of the loop (37, 38) (Fig. 2).
Remarkably, despite an unfavorable thermodynamic effect, a
Trp is present in this position in almost all the vertebrate spe-
cies (39), and it is crucial for the proper binding of 2-m to the
heavy chain of the major histocompatibility complex class I
(MHCI). In human 2-m, the Trp-60 can therefore play two
contrasting roles: a functional physiologic contribution to
the correct assembly of the major histocompatibility com-
plex class I and a detrimental, destabilizing, and pro-amy-
loidogenic effect when the plasma concentration of 2-m is
persistently high.
What Did the Comparison between the Amyloidogenesis
Mechanism of theWild Type and the Rare D76N Variant
Reveal?
Elucidation of themolecularmechanisms of rare diseases can
promote crucial progress in the interpretation of more general
phenomena aswell as illuminating themechanisms of common
diseases. The discovery of the rare natural amyloidogenic vari-
ant of2-m allowed a systematic analysis of its pathological and
biochemical features as well as providing the opportunity to
correlate specific molecular characteristics of the WT and of
the variant with peculiar clinical presentations and different
pathological features of the two related types of amyloidosis.
The first, associated with hemodialysis, is caused by the persis-
tently high concentration of 2-m in plasma, and it is charac-
terized by a selective localization of amyloid in bones and liga-
ments. The genetic form is not associated with any increase of
2-m in plasma, and the amyloid localization is mainly visceral,
involving liver, spleen, kidney, and heart, whereas, quite sur-
prisingly, bones and ligaments are spared. The original question
was: as far as this variant is concerned, which theories, hypoth-
esized to explain amyloidogenesis of WT 2-m, do remain
applicable? This question became particularly cogent once we
discovered the destabilizing effect of the mutation and the pos-
sibility to convert theD76N variant into amyloid fibrils in phys-
iologic buffer, by simply exposing the protein to fluid shear
forces in the presence of natural or artificial hydrophobic sur-
faces (40).
In WT 2-m, its intrinsic amyloidogenic propensity was
ascribed to its dynamic properties, particularly evident in the D
FIGURE1.Tappingmodeatomic forcemicroscopy imageof2-mamyloid
fibers in the presence of fibrillar collagen and heparin. Shown is the fibril
network connecting isolated collagen fibrils, observed after 24 h of incuba-
tion. Non-fibrillar aggregates are also present. Amplitude data: scan size, 5.7
m. This figure was originally published in The Journal of Biological Chemistry
(Relini, A., De Stefano, S., Torrassa, S., Cavalleri, O., Rolandi, R., Gliozzi, A., Gior-
getti, S., Raimondi, S., Marchese, L., Verga, L., Rossi, A., Stoppini, M., and Bel-
lotti, V. (2008) Heparin strongly enhances the formation of 2-microglobulin
amyloid fibrils in the presence of type I collagen. J. Biol. Chem. 283, 4912–
4920. © the American Society for Biochemistry and Molecular Biology).
FIGURE 2.2-m structure (Protein Data Bank (PDB) entry 2yxf) highlight-
ing the N-terminal peptide and three key residues: Pro-32, Trp-60, and
Asp-76. Exa N-terminal peptide, the six N-terminal residues lacking in
N62-m.
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strand and in the D-E loop region, whose flexibility is propelled
by the above mentioned Trp-60 (38). The comparative mea-
surement of the folding and unfolding kinetics as well as of the
native protein’s unfolding free energy allowed us to establish
that 5% of WT 2-m physiologically populates a partially
folded intermediate state and that the mutation D76N causes a
5-fold enhancement of the concentration of the intermediate at
the equilibrium in the physiological buffer (40).
Therefore, a direct correlation exists between the amyloido-
genic propensity of 2-m species and the concentration of this
partially structured intermediate. The structure of this inter-
mediate was extensively investigated, but it is still elusive due to
the high conformational dynamic on amicrosecond tomillisec-
ond time scale. A brilliant approach to single out specific char-
acteristics of this intermediate is based on the discovery that
several structural and functional features overlap those of
N62-m. A remarkable feature of both N62-m and the
folding intermediate I2 is most certainly the trans conforma-
tion of the His-Pro-32 peptide bond (27). The cis-trans transi-
tion is crucial for the fibrillogenesis, and it is a hallmark of the
fibrillar state (41, 42).
Although the amyloidogenic potential of the two 2-m spe-
cies (WT and D76N) is in agreement with the concentration of
the partially folded state at the equilibrium, a major and pecu-
liar difference emerges from the clinical/pathological features
of the two types of amyloidoses: notably, the localization in
bones and ligaments of the WT and the visceral localization of
the D76N. The amyloid deposition in bones is quite rare in
other systemic amyloidoses, but it is an unavoidable complica-
tion of DRA. The specific localization in bones and ligaments of
the amyloidosis caused by hemodialysis was ascribed to a pecu-
liar affinity of 2-m for type I and type II collagen. Nonetheless,
the measurement of the affinity constant of 2-m for collagen
revealed aweakKd of1 104 M (43). It is plausible to believe
that preferential accumulation of 2-m in collagen becomes
significant only for the micromolar concentration during
hemodialysis, whereas it does not become so in physiological
sub-micromolar concentrations. Furthermore, it is likely that
in DRA, the truncated N62-m species, which has a 10-fold
higher affinity to the full-length WT for collagen (43), is a
potent promoter of amyloidogenesis on the collagen surface
and that this is present only in the amyloid deposits localized in
bones and ligaments. The latter suggests that a protease, well
represented in the aforementioned tissues, could cleave 2-m
in its first strand, consequentially accelerating the local accu-
mulation of this conformer, which is then rapidly followed by
its fibrillar aggregation.
The mechanism by which collagen facilitates the amyloido-
genesis of 2-m is uncertain. Collagen offers wide hydrophobic
surfaces, and it is known that the flow of a physiologic fluid, at
the interface between polar and hydrophobic surfaces, can gen-
erate sufficient forces to partially or totally unfold a globular
protein (44). Hydrodynamic shear stress alone can generate
forces that can be quantified through the equation
T  Fs/A    dv/dx (Eq. 1)
where T represents the shear stress, Fs the shear force, A is the
cross-sectional area of the molecule,  is the dynamic viscosity
of the fluid, and dv/dx is the shear rate, which is the fluid veloc-
ity gradient.
However, the hydrophobic forces (FHydro) acting on themol-
ecule in the extracellular space play a dominant role in the pro-
tein destabilization, and they can be calculated according to
Mangione et al. (40) through the equation.
FHydroEHydro/d 2 Y a a0
 expd/Dhydro/Dhydro (Eq. 2)
where EHydro represents the hydrophobic interaction energies
between two apolar surfaces, Y is the interfacial tension, d is the
distance between the two surfaces, a is the exposed area of the
molecule at distance d, a0 is the optimum exposed area of
the molecule, which we consider to be equal to the area of one
amino acid, and Dhydro is the hydrophobic decay length.
We hypothesize that, in the extracellular matrix in the very
thin fluid space at the interface between hydrophobic surfaces
and the interstitial fluid, the amyloidogenic proteins could par-
tially unfold and expose normally buried hydrophobic patches.
These partially folded conformers could locally accumulate and
reach a condition of supersaturation (Fig. 3). Such a state is
extremely unstable, and several events can break solubility,
leading to protein precipitation. Although the shear flow of the
fluid is not per se sufficient to unfold globular proteins, it may
play a fundamental role in breaking the condition of supersat-
uration. In fact, in conditions of supersaturation, the intensity
of shear flow inversely correlates to the lag phase of 2-m fibril-
logenesis (45). All these data suggest that the concentration of
2-m and its level of thermodynamic stability could direct the
amyloid formation in two distinct tissue targets. In conditions
of high concentration, but relatively good thermodynamic sta-
bility, the amyloid is deposited in bones and ligament. When
plasma concentration is low, implying a negligible accumula-
tion of 2-m on the collagen surface, bones and ligaments are
spared. If a mutation reduces the stability of 2-m (i.e. D76N
mutation), the shear stress in the extracellularmatrix of visceral
organs such as liver, spleen, kidney, and heart is sufficient to
unfold the unstable variant and prime a cascade of events as
represented in Fig. 3. It is worth noting that the amyloid depos-
its of patients heterozygous for themutation D76N do not con-
tain the WT 2-m. However, in vitro, once D76N fibrils are
formed, shear stress, generated by the dynamics of a physiologic
fluid and the exposure to hydrophobic surface of biological
molecules, can also prime amyloidogenesis of WT 2-m (40).
These findings are apparently incompatible, but let us grasp the
complexity of amyloidogenesis in vivo. The demonstration that,
in the presence of a generic extracellular chaperone such as B
crystallin, even in a very lowmolar ratio, theWT2-mbecomes
resistant to the fibrillar conversion induced by the D76N fibrils
(40) suggests that in vivo factors such as chaperones can mod-
ulate the amyloidogenesis of WT proteins.
The Existence of Natural Factors Modulating
Amyloidogenesis
The discovery that forces physiologically harboring the
human tissues are sufficient to prime the protein unfolding and
fibrillogenesis (44) sheds light on the pathophysiology of amy-
MINIREVIEW: 2-m Amyloidosis
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loid formation. However, a deep gap still exists between the in
vitro and in vivo conditions of protein amyloidogenesis. The in
vitro investigation usually concerns the transition of an isolated
and homogeneousmolecule, but in vivo the amyloidogenic pro-
tein interplays with a variety of other chemical entities and
peculiar physical environments. In vivo an equilibrium exists
between pro-fibrillogenic and anti-fibrillogenic factors. In the
interstitial space, where the amyloid deposits are formed, a few
proteins could specifically influence the aggregation propensity
of amyloidogenic proteins. Albumin per se, which is present in
the interstitial space at a concentration around 10 mg/ml, can
partially inhibit the fibrillogenesis by improving the protein’s
colloidal stability. However, more specific and more effective
inhibitors of protein aggregation are present in the extracellular
space where chaperones play a rather important role (46). In
2-m amyloidosis, the anti-fibrillogenic properties of some of
these chaperones were specifically studied, namely the 2-M
(47) and, as mentioned above, B-crystallin (48). The mecha-
nismbywhich in vitro2-M interfereswith2-m amyloidogen-
esis reveals that the most effective species is a dimeric form of
2-M, resulting from the stress-mediated dissociation of the
tetramer. It was demonstrated that 2-M binds the unfolded
2-mmore avidly than the folded one (47). These findings sug-
gest that conditions promoting at once the unfolding of the
amyloidogenic protein as well as the structural rearrangement
of the chaperone could activate the chaperone function of
2-M. Consistent with the in vitro and ex vivo studies, it was
also demonstrated that although 2-M inhibits 2-m aggrega-
tion, it is nonetheless unable to disaggregate mature fibrils.
Other extracellular chaperones display similar properties.
B-crystallin is capable of inhibiting fibrillogenesis when added
in sufficient quantity to competewith the self-assembly of2-m
variant and, as mentioned above, to dissociate the aggregation
of WT and variant (48). However, once the fibrils are formed,
chaperones, such as 2-M, are unable to solubilize the amyloid
and co-precipitate with the mature fibrils.3
The general function of extracellular chaperones in amy-
loidogenesis is well characterized in clusterin. The capacity of
clusterin to interfere with amyloid formation was not tested on
2-m, but on apolipoproteinC-II (49), lysozyme (50), synuclein,
and other amyloidogenic proteins (51, 52). Similarly to 2-M
and crystallin, clusterin is also unable to dissociate preformed
fibrils, and it is frequently found as a bystander component of
natural amyloid fibrils.
The emerging scenario is consistent with the hypothesis
that these extracellular chaperones could perform a dual,
apparently antithetical function, notably the inhibition of
oligomerization and fibrillogenesis acting on the solubility of
partially folded intermediates as well as the stabilization of
amyloid fibrils once these are formed. The balance between
these two functions in the formation of amyloid in the nat-
ural environment is yet to be determined, but it is most prob-
ably crucial for the elucidation of the natural history of the
disease and the possible therapeutic exploitation of these
molecules.
3 V. Bellotti et al., unpublished data.
FIGURE 3. Schematic picture of the hypothetical events occurring in the interstitial space where globular soluble proteins undergo fibrillar conver-
sion. The chemical physical characteristics of the interstitial space and forces generated by the fluid flow are well reviewed by Swartz and Fleury (61). Native
globular proteins flow through a network of fibrous proteins (i.e. collagen and elastin) and GAGs. These matrix proteins expose hydrophobic patches with
which the native globular proteins collide. At the interface between the hydrophobic surface and the aqueous fluid, proteins are exposed to forces sufficient
to perturb the folded state. The exposure of normally buried hydrophobic elements further facilitates the interaction with the hydrophobic matrix, local
accumulationof partially foldedglobular conformers reaching a condition of supersaturation. Supersaturation is theprecondition for protein aggregation and
loss of solubility. Evenminimal changes in the intensity of the shear flow can break the very labile soluble state of partially folded proteinswhen they reach the
condition of supersaturation. If supersaturation is not reached, the simple unfolding of the proteins does not imply a fibrillar conversion and the protein can
properly refold and escape from the aggregation.
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2-m Pharmaceutical Interactants and Amyloidogenesis
Inhibition
Besides extracellular chaperone proteins, other compounds
can inhibit 2-m amyloidogenesis through different mecha-
nisms. As a prototype of a generic inhibitor of amyloidogenesis,
we proved that in vitro the antibiotic doxycycline can inhibit
the amyloidogenesis of WT 2-m (53), and with a similar dose,
it can affect the fibrillogenesis of the natural variant D76N.3
The main obstacle to in vivo doxycycline therapeutic efficacy
was expected to be the difficulty in obtaining a therapeutic con-
centration. However, the concentration of doxycycline in the
tissue targets proved to bemuch higher than in plasma (54) and
most likely sufficient to inhibit aggregation of oligomers and
2-m toxicity. Preliminary data, obtained in the first three
patients affected by DRA and treated with doxycycline, suggest
that a therapeutic response can be achieved even with a plas-
matic concentration that is apparently insufficient to abrogate
fibrillogenesis in vitro (55). Specific small ligands of an amy-
loidogenic protein can be therapeutically used, as the ligand-
mediated stabilization can be sufficient to protect from the
unfolding and aggregation. The best example for this approach
is the stabilization of TTR through small analogues of its natu-
ral ligands (56). However, no specific small ligands with similar
properties are available for 2-m. An immunological approach,
mainly based on the use of specific antibodies, can probably be
properly pursued for this amyloidosis. We previously showed
that the specific monovalent single chain camelid antibodies
can inhibit wild type amyloidogenesis (57), andwe are confirm-
ing their effect on the Asn-76 variant.3 In the absence of other
possible therapies and considering the relatively low concentra-
tion of circulating 2-m, a treatment-based antibody should be
pursued in the familial form of 2-m amyloidosis, and once its
efficacy is demonstrated, it could be extended to other forms of
systemic amyloidoses.
Concluding Remarks
The extensive research carried out on2-m-related amyloid-
osis has substantially contributed to elucidating the general
rules dictating the amyloid conversion of globular proteins in
systemic amyloidosis. To self-aggregate into a cross- struc-
tured fibrils, the amyloidogenic globular protein must partially
unfolded. The loss of the native structure can be primarily
caused by mutations of covalent modifications such as limited
proteolytic cleavages. WT 2-m is a paradigmatic example of
how the aggregation risk of some proteins, exposing hydropho-
bic and flexible regions for functional reasons, is controlled by
maintaining very low protein concentrations. The risk of pro-
tein aggregation becomes instead extremely high when a con-
dition of supersaturation of the partially folded intermediates
occurs in the extracellular space of the target organs. Investiga-
tions of 2-mmodels have provided unique new insights eluci-
dating the mechanism of selective tissue targeting in other
forms of systemic amyloidosis, where the amyloid is deposited
in organs distant from the synthesis site. The most common
forms of systemic amyloidosis, such as those caused by immu-
noglobulin light chains, TTR, lysozyme, and lipoproteins, are
prototypic examples of instances when the sites of production
and of major deposition are totally different. It is now possible
to address the crucial and challenging question of the role
played by local tissue factors in favoring and contrasting protein
aggregation. The equilibrium between these factors probably
determines the peculiar natural history of the different types of
systemic amyloidosis. It is plausible that even within the same
type of amyloid diseases, these factors will influence the precise
medical and pathologic features of the individual patient.
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